Connective tissue diseases: Immunosuppressive therapy in SSc: What is the target?

Nature Reviews Rheumatology

Volumn 5, Issue 7, 2009, Pages 357-358

  Boin, Francesco ^a   Wigley, Fredrick ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT;

DRUG COMBINATION; FIBROSIS; HUMAN; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; NOTE; PATHOPHYSIOLOGY; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME;

DRUG THERAPY, COMBINATION; FIBROSIS; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 70349577780     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2009.108     Document Type: Article

References (6)

1. Hunzelmann, N. et al. High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy. Arthritis Res. Ther. 11, R30 (2009).
2. Kowal-Bielecka, O. et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR scleroderma Trials and Research group (EUSTAR). Ann. Rheum. Dis. 68, 620–628 (2009).
3. Boin, F. & Rosen, A. Autoimmunity in systemic sclerosis: current concepts. Curr. Rheumatol. Rep. 9, 165–172 (2007).
4. Bérezné, A. et al. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. J. Rheumatol. 35, 1064–1072 (2008).
5. Tashkin, D. P. et al. Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. 354, 2655–2666 (2006).
6. Distler, J. & Distler, O. Novel treatment approaches to fibrosis in scleroderma. Rheum. Dis. Clin. North Am. 34, 145–159 (2008).